Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis
Onno W. Akkerman, Floris Grasmeijer, Wiel C.M. de Lange, Huib A.M. Kerstjens, Gerard de Vries, Mathieu S. Bolhuis, Jan-Willem Alffenaar, Henderik W. Frijlink, Grace Smith, Roger Gajraj, Rina de Zwaan, Paul Hagedoorn, Martin Dedicoat, Dick van Soolingen, Tjip S. van der Werf
European Respiratory Journal 2018 51: 1702490; DOI: 10.1183/13993003.02490-2017
Onno W. Akkerman
1University of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands
2University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, The Netherlands
13Both authors contributed equally
Floris Grasmeijer
3University of Groningen, Dept of Pharmaceutical Technology and Biopharmacy, Groningen, The Netherlands
13Both authors contributed equally
Wiel C.M. de Lange
1University of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands
2University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, The Netherlands
Huib A.M. Kerstjens
1University of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands
Gerard de Vries
4KNCV Tuberculosis Foundation, Den Haag, The Netherlands
5Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
Mathieu S. Bolhuis
6University of Groningen, University Medical Center Groningen, Dept of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands
Jan-Willem Alffenaar
6University of Groningen, University Medical Center Groningen, Dept of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands
Henderik W. Frijlink
3University of Groningen, Dept of Pharmaceutical Technology and Biopharmacy, Groningen, The Netherlands
Grace Smith
7National Mycobacteriology Reference Unit, Birmingham, UK
Roger Gajraj
8Public Health England, Birmingham, UK
Rina de Zwaan
9National Tuberculosis Reference Laboratory, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
Paul Hagedoorn
3University of Groningen, Dept of Pharmaceutical Technology and Biopharmacy, Groningen, The Netherlands
Martin Dedicoat
10Dept of Infection, Heart of England Foundation Trust, Birmingham, UK
Dick van Soolingen
9National Tuberculosis Reference Laboratory, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
11Radboud University Nijmegen Medical Centre, Depts of Pulmonary Diseases and Medical Microbiology, Nijmegen, The Netherlands
Tjip S. van der Werf
1University of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands
12University of Groningen, University Medical Center Groningen, Dept of Internal Medicine, Groningen, The Netherlands
Vol 51 Issue 3
Table of Contents
Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis
Onno W. Akkerman, Floris Grasmeijer, Wiel C.M. de Lange, Huib A.M. Kerstjens, Gerard de Vries, Mathieu S. Bolhuis, Jan-Willem Alffenaar, Henderik W. Frijlink, Grace Smith, Roger Gajraj, Rina de Zwaan, Paul Hagedoorn, Martin Dedicoat, Dick van Soolingen, Tjip S. van der Werf
European Respiratory Journal Mar 2018, 51 (3) 1702490; DOI: 10.1183/13993003.02490-2017
Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis
Onno W. Akkerman, Floris Grasmeijer, Wiel C.M. de Lange, Huib A.M. Kerstjens, Gerard de Vries, Mathieu S. Bolhuis, Jan-Willem Alffenaar, Henderik W. Frijlink, Grace Smith, Roger Gajraj, Rina de Zwaan, Paul Hagedoorn, Martin Dedicoat, Dick van Soolingen, Tjip S. van der Werf
European Respiratory Journal Mar 2018, 51 (3) 1702490; DOI: 10.1183/13993003.02490-2017